|Table of Contents|

Relationship between the short-term efficacy of 131I treatment for papillary thyroid carcinoma with cervical lymph node metastasis and the pathological characteristics

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2025 06
Page:
955-959
Research Field:
Publishing date:

Info

Title:
Relationship between the short-term efficacy of 131I treatment for papillary thyroid carcinoma with cervical lymph node metastasis and the pathological characteristics
Author(s):
LIU Cong1; XU Xiang2; GUO Yanjun1; WANG Guoqiang3; SHEN Baoming4; ZHAO Wenjuan1; LI Chengqian1
1.Department of Endocrinology and Metabolism;2.Department of Geriatrics;3.Department of Nuclear Medicine;4.Department of Information Management,the Affiliated Hospital of Qingdao University,Shandong Qingdao 266000,China.
Keywords:
papillary thyroid carcinoma; cervical lymph node metastasis; 131I treatment; short-term efficacy
PACS:
R736.1
DOI:
10.3969/j.issn.1672-4992.2025.06.010
Abstract:
Objective:To investigate the relationship between the short-term efficacy for the first postoperative 131I therapy in patients with papillary thyroid cancer(PTC) with cervical lymph node metastasis(CLNM) and the pathological characteristics.Methods:A retrospective analysis of 327 patients with PTC with CLNM,with a median follow-up time of 8.3 months,was performed and divided into an optimal treatment excellent response(ER) group and a non-excellent response(NER) group based on the assessment results.Clinicopathological characteristics were compared between the 2 groups,and Logistic regression analysis was performed to evaluate the predictive value of ps-Tg on ER and the optimal cut-off value.Results:The ER rate was 58.4%(191/327).In the ER group,the single primary tumor,the unilateral primary tumor,the maximum diameter of the primary tumor≤1 cm,no extracapsular invasion,the maximum diameter of metastatic lymph nodes＜1 cm,the number of metastatic lymph nodes＜5,ps-Tg＜5.66 ng/mL were higher than those in the NER group(all P<0.05).Multifactorial analysis showed that only primary carcinoma unifocal and unilateral were not correlated with ER,while all the remaining index status were positively correlated with ER(all P<0.05).The area under the ROC curve(AUC) for the relationship between ps-Tg and ER was 0.779,and the optimal cut-off value for predicting ER was 7.5 ng/mL,with the sensitivity,specificity and accuracy of 75.9%,76.5% and 76.1%,respectively.Conclusion:PTC patients with CLNM treated by 131I have a higher ER rate in the short term.The diameter of the primary lesion ≤ 1 cm,no extracapsular invasion,the diameter of metastatic lymph nodes<1 cm,the number of metastatic lymph nodes<5,and ps-Tg<5.66 ng/mL are independent risk factors for predicting ER.ps-Tg≤7.5 ng/mL indicates a higher probability of reaching ER.

References:

［1］GAO YJ,LI B,WU XY,et al.Thyroid tumor-initiating cells:Increasing evidence and opportunities for anticancer therapy(review)［J］.Oncol Rep,2014,31(3):1035-1042.
[2] BAUDIN E,SCHLUMBERGER M.New therapeutic approaches for metastatic thyroid carcinoma［J］.Lancet Oncol,2007,8(2):148-156.
[3]侯伟,李佳,谢守凤,等.甲状腺乳头状癌颈淋巴结转移规律与手术方式的选择［J］.现代肿瘤医学,2017,25(16):2576-2580. HOU W,LI J,XIE SF,et al.Surgical method of papillary thyroid carcinoma according to the metastatic patterns of lymph nodes in the neck［J］.Modern Oncology,2017,25(16):2576-2580.
[4] LEE J,SOH EY.Differentiated thyroid carcinoma presenting with distant metastasis at initial diagnosis clinical outcomes and prognostic factors［J］.Ann Surg,2010,251(1):114-119.
[5]HAUGEN BR,ALEXANDER EK,BIBLE KC,et al.2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer:The American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer［J］.Thyroid,2016,26(1):1-133.
[6]TUTTLE RM,TALA H,SHAH J,et al.Estimating risk of recurrence in differentiated thyroid cancer after total thyroidectomy and radioactive iodine remnant ablation:Using response to therapy variables to modify the initial risk estimates predicted by the new American Thyroid Association staging system［J］.Thyroid,2010,20(12):1341-1349.
[7]VAISMAN F,MOMESSO D,BULZICO DA,et al.Spontaneous remission in thyroid cancer patients after biochemical incomplete response to initial therapy［J］.Clin Endocrinol,2012,77(1):132-138.
[8]EROL V,MAKAY O,ICOZ G,et al.Prognostic factors of survival and recurrence pattern in differentiated thyroid cancer:A retrospective study from Western Turkey［J］.Endocr Regul,2014,48(4):173-181.
[9]胡厚洋,梁军,林岩松.影响分化型甲状腺癌131I治疗获得最佳疗效反应的因素分析及治疗后的动态评估［J］.中国肿瘤临床,2018,45(01):18-21. HU HY,LIANG J,LIN YS.Influencing factors to excellent response in differentiated thyroid cancer after 131I therapy and ongoing assessment［J］.Chinese Journal of Clinical Oncology,2018,45(01):18-21.
[10]RANDOLPH GW,DUH QY,HELLER KS,et al.The prognostic significance of nodal metastases from papillary thyroid carcinoma can be stratified based on the size and number of metastatic lymph nodes,as well as the presence of extranodal extension［J］.Thyroid,2012,22(11):1144-1152.
[11]MANSOUR J,SAGIV D,ALON E,et al.Prognostic value of lymph node ratio in metastatic papillary thyroid carcinoma［J］.J Laryngol Otol,2018,132(1):8-13.
[12]高文,梁军,赵腾,等.甲状腺乳头状癌淋巴结转移率与131I治疗后临床转归的关系［J］.中国癌症杂志,2016,26(01):67-72. GAO W,LIANG J,ZHAO T,et al.The impact of lymph node metastatic rate on clinical outcome following 131I therapy in patients with papillary thyroid carcinoma［J］.China Oncology,2016,26(01):67-72．
[13]刘杰蕊,梁军,林岩松.分化型甲状腺癌131I治疗前刺激性Tg与最佳治疗反应的关系［J］.中国癌症杂志,2019,29(02):125-130. LIU JR,LIANG J,LIN YS.Relationship between preablative stimulated thyroglobulin and the excellent response in differentiated thyroid carcinoma［J］.China Oncology,2019,29(02):125-130.
[14]XU X,LI C,YU X,et al.Clinicopathological features affecting the efficacy in 131I ablation therapy of papillary thyroid carcinoma with lymph node metastasis［J］.Frontiers in Endocrinology,2024,15:1382009.
[15]MCLEOD DS,COOPER DS,LADENSON PW,et al.Prognosis of differentiated thyroid cancer in relation to serum thyrotropin and thyroglobulin antibody status at time of diagnosis［J］.Thyroid,2014,24(1):35-42.
[16]GONZALEZ C,AULINAS A,COLOM C,et al.Thyroglobulin as early prognostic marker to predict remission at 18~24 months in differentiated thyroid carcinoma［J］.Clin Endocrinol(Oxf),2014,80(2):301-306.
[17]陈思涵,汪君瑶,程歆琦,等.甲状腺球蛋白在分化型甲状腺癌诊治中的应用［J］.中华转移性肿瘤杂志,2024,7(2):165-168. CHEN SH,WANG JY,CHENG XQ,et al.The clinical application of thyroglobulin in differentiated thyroid carcinoma［J］.Chinese Journal of Metastatic Cancer,2024,7(2):165-168.
[18]贾朝阳,李德宇,王森,等.PsTg联合淋巴结转移率在甲状腺乳头状癌患者131I治疗预后中的应用价值［J］.中华核医学与分子影像杂志,2023，43(07):407-411. JIA CY,LI DY,WANG S,et al.Application value of psTg combined with lymph node rationprognosis of papillary thyroid cancer patients treated with 131I［J］.Chinese Journal of Nuclear Medicine and Molecular Imaging,2023,43(07):407-411.
[19]WATANABE K,UCHIYAMA M,FUKUDA K.The outcome of I-131 ablation therapy for intermediate and high-risk differentiated thyroid cancer using a strict definition of successful ablation［J］.Jpn J Radiol,2017,35(9):505-510.
[20]HUSSEINI MA.Implication of different clinical and pathological variables in patients with differentiated thyroid cancer on successful ablation for 3 700 MBq 131I:A single Egyptian institutional experience over 14 years［J］.Ann Nucl Med,2016,30(7):468-476.
[21]TAMILIA M,AL-KAHTANI N,ROCHON L,et al.Serum thyroglobulin predicts thyroid remnant ablation failure with 30 mCi iodine-131 treatment in patients with papillary thyroid carcinoma［J］.Nucl Med Commun,2011,32(3):212-220.
[22]POLACHEK A,HIRSCH D,TZVETOV G,et al.Prognostic value of post-thyroidectomy thyroglobulin levels in patients with differentiated thyroid cancer［J］.J Endocrinol Invest,2011,34(11):855-860.
[23]LIN JD,HUANG MJ,HSU BR,et al.Significance of postoperative serum thyroglobulin levels in patients with papillary and follicular thyroid carcinomas［J］.J Surg Oncol,2002,80(1):45-51.
[24] 郭卫,李智勇,朱辉,等.分化型甲状腺癌患者术后再次 131I治疗疗效的影响因素分析［J］.实用肿瘤杂志,2024,39(03):270-275. GUO W,LI ZY,ZHU H,et al.Influencing factors of therapeutic effects of 131I re-ablation treatment on differentiated thyroid cancer［J］.Journal of Practical Oncology,2024,39(03):270-275.
[25] 王芳,王越,刁宏翠,等.分化型甲状腺癌术后再次131I治疗前sTg与sTg/sup-Tg对淋巴结转移的预测价值［J］.现代肿瘤医学,2020,28(14):2417-2421. WANG F,WANG Y,DIAO HC,et al.The predictive value of sTg and sTg /sup － Tg on lymph node metastasis of differentiated thyroid cancer before the second 131I ablation［J］.Modern Oncology,2020,28(14):2417-2421.

Memo

Memo:
山东省自然科学基金(编号：ZR2022QH127)
Last Update: 1900-01-01